Apellis Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-13

Reporting Person: GELLERT MICHAEL E (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-13	Common Stock	C	798068	—	Acquired	943989	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-13	Series A Preferred Stock	$	C	600000	Disposed		Common Stock (281293)	Direct
2017-11-13	Series B Preferred Stock	$	C	545454	Disposed		Common Stock (255721)	Direct
2017-11-13	Series C Preferred Stock	$	C	556830	Disposed		Common Stock (261054)	Direct

Footnotes

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.